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Objective: We investigated possible associations between neurotoxic inflammatory 
mediators (IMs) and anti-U1RNP antibodies (Abs) in cerebrospinal fluid (CSF) of 
neuropsychiatric systemic lupus erythematosus (NPSLE). 
Methods: Serum and CSF anti-U1RNP Abs were detected using an 
RNA-immunoprecipitation assay and CSF anti-U1RNP Ab levels were measured by ELISA. 
IFN-α, MCP-1 and IL-8 levels in CSF were determined by quantitative multiplex cytokine 
analysis. IM levels were compared among anti-U1RNP-positive and anti-U1RNP -negative 
NPSLE as well as other rheumatic disease controls (controls). 
Results: Anti-U1RNP Abs were detected in serum (58%) and in CSF (18%) of 82 NPSLE 
patients. CSF MCP-1 levels were higher in NPSLE than in controls. CSF IFN-α level was 
higher in CSF anti-U1RNP Ab-positive than in -negative patients or controls. When limited 
to serum anti-U1RNP Ab-positive patients, however, levels of all 3 IMs in CSF were higher 
in CSF anti-U1RNP Ab-positive than in -negative patients. Anti-U1RNP Ab levels in CSF 
correlated with CSF MCP-1, but not IFN-α and IL-8 levels.  
Conclusions: CSF anti-U1RNP Ab positivity is associated with the increased level of CSF 
IFN-α. MCP-1 levels correlated with CSF anti-U1RNP Ab levels, whereas the increased CSF 
MCP-1 was not specific to CSF anti-U1RNP Ab-positive NPSLE. 
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Systemic lupus erythaematosus (SLE) is a chronic multisystem autoimmune disease, and 
neuropsychiatric SLE (NPSLE) is a severe life-threatening condition. Although the 
pathophysiology of NPSLE remains unclear, a particular subset of autoantibodies (auto-Abs) 
has been shown to be associated with neuronal injury.[1-3] Abs binding to a certain sequence 
of the N-methyl-D-aspartate receptor subunit NR2 (anti-NR2 Abs) cause excitatory synaptic 
transmissions in central nervous system (CNS).[4] Arinuma et al[5] reported that anti-NR2 
Abs in the cerebrospinal fluid (CSF), but not in serum, were involved in diffuse central 
NPSLE. Okada et al[6] reported that 13 of 14 patients (7 SLE, 5 mixed connective tissue 
disease [MCTD] or overlap syndrome, 1 undifferentiated CTD, 1 Sjögren’s syndrome) with 
aseptic meningitis attributed to CTD had serum anti-U1 ribonucleoprotein (RNP) Abs. 
Recently, using an RNA-immunoprecipitation assay (RNA-IPP), we found that anti-U1RNP 
Abs were detected in CSF; anti-U1RNP Abs in CSF could be a useful biomarker of NP 
manifestations in SLE.[7]  
In addition to auto-Abs, inflammatory mediators (IMs) have been found in CSF of 
NPSLE patients.[8, 9] Previous reports showed that the levels of IFN-α[10], IFN-γ-inducible 
protein (IP)-10[11, 12], IL-8[11], monocyte chemotactic protein (MCP)-1[11, 13], 
fractalkine (CX3CL1)[14], the regulated and normal T-cell expressed and secreted 
(RANTES/CCL5) chemokine[11] and IFN-γ-induced monokines (MIG/CXCL9)[11] in CSF 
are significantly higher in NPSLE than in non-NPSLE patients. IFN-α production in SLE is 
caused, at least partially, by auto-Abs binding to RNP particles released from dead or dying 
cells.[15, 16] Santer et al[17] suggested that IFN-inducing activity in CSF correlates with 
serum anti-U1RNP Abs but not with other known anti-nuclear Abs. Therefore, anti-U1RNP 
Abs and/or their immune complexes (IC) in CSF may play a pathogenic role in NPSLE; 
however, the association between CSF anti-U1RNP Abs and IMs remains unclear. In this 
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study, we examined the levels of anti-U1RNP Abs and IMs in serum and CSF samples from 





Eighty-two SLE patients (70 female, 12 male) with NP manifestations admitted to 
the Department of Rheumatology and Clinical Immunology, Kyoto University Hospital, 
between March 2003 and October 2011 were enrolled in this study. Patient age at NP 
manifestation onset was 36.3 ± 15.1 years (range, 10–75 years) (Table 1). SLE was 
diagnosed according to the ACR criteria [18, 19]. NP manifestations were determined 
according to case definitions for NP syndromes in SLE[20] following NP testing, 
electroencephalography and brain MRI. NP manifestations caused by other factors (e.g., 
concurrent non-SLE NP diseases such as infection, uraemia and drug-induced aseptic 
meningitis) were excluded from this study. After obtaining informed consent from all 
participants, CSF and serum samples were obtained on the same day and stored at −80°C 
until analysis. Control CSF samples were obtained from 15 patients with other systemic 
rheumatic diseases including rheumatoid arthritis (4), vasculitis (7), Behçet disease (3) and 
TNF receptor-associated periodic syndrome (1) (all anti-U1RNP Ab negative; 5 men and 10 
women with age of 42.7 ± 20.6 years). Although these patients had NP manifestations, 
routine laboratory analysis of CSF (e.g., protein level) was normal. The present study was 
carried out in compliance with the Helsinki Declaration and approved by the Kyoto 
University Ethics Committee Review Board (Approved #E97). 
 
CSF IM detection 
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CSF was routinely analysed for total protein levels, cell number and IgG levels. 
IFN-α, IL-8 and MCP-1 levels were determined using the Procarta® Cytokine Assay Kit 
(Affymetrix Inc., Santa Clara, CA, USA) and quantitative multiplex cytokine analysis was 
performed with Bio-Plex® (Bio-Rad Laboratories, Hercules, CA, USA).  
 
Detection of anti-RNA-binding proteins (RBPs) in serum and CSF by RNA 
immunoprecipitation (RNA-IPP).  
RNA-IPP using HeLa-cell extracts was performed [7, 21] to detect anti-U1RNP, Sm, 
Ro/SSA (SSA) and La/SSB (SSB) Abs in serum and CSF samples. Briefly, 10 μl of the 
sample was mixed with 2 mg of protein A SepharoseTM CL-4B (GE Healthcare) in IPP buffer 
[10-mM Tris–HCl, pH 8.0; 500-mM NaCl; 0.1% Nonidet P-40 (NP-40)] and incubated for 2 
h at 4°C. The IgG-coated SepharoseTM beads were then washed in IPP buffer and 
resuspended in NET-2 buffer (50-mM Tris–HCl, pH 7.5; 150-mM NaCl; 0.05% NP-40). For 
RNA analysis, this suspension was incubated with HeLa-cell extracts derived from 6 × 106 
cells for 2 h at 4°C. The antigen-bound SepharoseTM was then collected, washed and 
resuspended in NET-2 buffer. To extract bound RNA, 30 µl of 3.0-M sodium acetate, 15 µl 
of 20% sodium dodecyl sulphate and 300 µl of phenol/chloroform/isoamyl alcohol (50:50:1) 
solution, which is saturated with 0.1M Tris-HCl pH 7.5 (about 100ml/l) and contains 0.1% 
8-hydroxyquinoline, were added to the SepharoseTM beads. RNA was recovered in the 
aqueous phase after ethanol precipitation and dissolved in electrophoresis sample buffer 
consisting of 10-M urea, 0.025% bromophenol blue and 0.02% xylene cyanol FF (Bio-Rad) 
in Tris–borate–EDTA buffer (90-mM Tris–HCl, pH 8.6; 90-mM boric acid; 1-mM EDTA). 
The RNA samples were denatured at 65°C for 5 min and then resolved by 7-M urea–10% 
PAGE with silver staining (Bio-Rad). Anti-U1RNP, Sm, SSA and SSB Abs were detected as 
positive when U1RNA, U1-U6RNA, SSA-RNA (Y1-Y5RNA) and SSB-RNA (5S-ribosomal 
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RNA, 7S-RNA and Y1-Y5RNA), respectively, were precipitated.  
 
Measurement of anti-U1RNP Ab levels in CSF by ELISA 
CSF anti-U1RNP Ab levels were determined by ELISA using recombinant U1RNP 
(Mesacup®-2 test RNP, Medical and Biological Laboratories (MBL) Co., Nagoya, Japan) 
according to the manufacturer’s protocol. CSF samples were diluted 1:5 using 
phosphate-buffered saline (PBS). Patient CSF were incubated as primary Abs at room 
temperature for 2 h, and bound IgG was detected with alkaline phosphatase-conjugated 
anti-human IgG (Southern Biotechnology Associates Inc., Birmingham, AL, USA) at OD405 
nm in a microtitre ELISA reader. All assays were performed in triplicate and OD405 nm values 
of CSF samples were confirmed to be within the linear range of the positive control.  
 
Statistical analysis 
The non-parametric Mann–Whitney U test was used to compare levels between the 
means of 2 groups. Spearman’s correlation coefficient by the rank test was used to evaluate 





Anti-U1RNP Abs detected in serum and CSF of NPSLE patients 
Auto-Abs against RBPs were examined using RNA-IPP (Figure 1). Serum 
anti-U1RNP Abs were positive in 58% patients (Figure 2). CSF anti-U1RNP Abs were 
detected in 15 patients (18% of all patients or 31% of serum anti-U1RNP Ab-positive 
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patients); CSF anti-SSA Abs were detected in 4 patients (5% of all patients and 8% of serum 
anti-SSA Ab-positive patients). Both anti-U1RNP and SSA Abs in CSF were negative in 
patients without serum anti-U1RNP and SSA Abs. Serum and CSF anti-Sm Abs were 
positive in 4 patients and 1 patient, respectively. CSF anti-SSB Abs were not detected in our 
patients. Because of the low frequency of CSF anti-SSA/Sm Abs and our previous data [7], 
we only analysed the association between anti-U1RNP Abs and CSF IMs. There was no 
significant association of serum or CSF anti-U1RNP Ab positivity with NPSLE forms in our 
patients (Table 1). Also, there was no correlation between serum and CSF anti-U1RNP Ab 
levels (data not shown and refer to Ref. 7). Abs against ribosomal proteins such as 28S 
ribosome were detected in 7 patients’ sera, but not in CSF. 
 
Association of serum anti-U1RNP Abs and CSF IMs 
As shown in Figure 3, there was no significant difference in CSF IFN-α and IL-8 
levels between serum anti-U1RNP Ab-positive patients and controls. CSF MCP-1 level was 
significantly elevated in NPSLE than in controls.  
 
Association of CSF anti-U1RNP Abs and CSF IMs 
IFN-α levels in CSF anti-U1RNP Ab-positive patients, but not in CSF anti-U1RNP 
Ab-negative, were significantly higher than in controls (Figure 4A). CSF MCP-1 levels in 
NPSLE patients were markedly elevated irrespective of CSF anti-U1RNP Ab positivity.  
CSF anti-U1RNP Abs were not detected in serum anti-U1RNP-negative patients. 
When limited to serum anti-U1RNP Ab-positive patients, CSF levels of all 3 IMs were 
higher in CSF anti-U1RNP Ab-positive patients than in CSF anti-U1RNP Ab-negative 
patients (Figure 4B). 
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Correlation of anti-U1RNP Ab levels with IM concentrations in CSF 
Among 15 CSF anti-U1RNP Ab-positive patients, 12 of CSF samples were 
remained enough for determination of anti-U1RNP Ab levels by ELISA. In NPSLE patients 
with CSF anti-U1RNP Abs, the Ab level correlated with CSF MCP-1 concentration but not 
with CSF IFN-α (Figure 5). CSF IL-8 concentration did not correlate with CSF anti-U1RNP 
Ab level (data not shown). 
 
Discussion 
We previously showed that CSF anti-U1RNP Abs detected by RNA-IPP are more 
specific markers for primary central NPSLE than CSF IL-6 concentration and IgG index in 
serum anti-U1RNP Ab-positive patients.[7] However, how CSF anti-U1RNP Abs are 
correlated with the NPSLE pathogenesis remains unclear. To solve this question, we 
collected CSF samples of SLE patients with NP manifestations widely, including patients 
whose NP symptoms were not so severe. Therefore, positivity of CSF anti-U1RNP Abs in 
the present study was less frequent than that in the previous study. [7] 
This study is the first one to show a significant association between CSF 
anti-U1RNP Abs and particular subsets of IMs in NPSLE patients. CSF IFN-α levels were 
increased only in patients with CSF anti-U1RNP Abs, suggesting anti-U1RNP Ab-mediated 
IFN-α production in CNS. Santer et al[17] reported that IC-containing CSF-IgG of NPSLE 
patients had abnormally high IFN-α-inducing activity. This phenomenon was most 
prominent in serum anti-U1RNP Ab-positive patients, which supports our results. IFN-α was 
detected in CSF of NPSLE patients; therefore, it might be induced by intrathecal complexes 
of anti-U1RNP Ab and IC.  IFN-α production has a pathogenic significance in SLE [22]; 
therefore, CSF anti-U1RNP Ab-associated NP manifestations should be analysed in future 
studies. Although the percentages of diffuse psychiatric and neuropsychological syndromes 
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were similar in our patients, symptoms of NPSLE patients with CSF anti-U1RNP Abs 
appeared to be relatively limited to headache and psychosis. In most of the patients with 
these diagnoses, however, CSF anti-U1RNP Abs are negative. Recently, Fragoso–Loyo et 
al[23] reported that CSF IFN-α was not a useful biomarker of central NPSLE. Our data 
suggested that no elevation of CSF IFN-α levels occurred in patients without CSF 
anti-U1RNP Abs and that an increased CSF IM levels may depend on the specificity of CSF 
auto-Abs. IL-8 and MCP-1 synthesis might be regulated by other auto-Abs in CSF. The 
reason why CSF IFN-α concentrations did not correlate with CSF anti-U1RNP Ab levels 
could not be elucidated in the present study. In our NPSLE patients, IgG index is 
significantly higher in CSF anti-U1RNP Ab-positive than in CSF anti-U1RNP Ab-negative 
patients (unpublished data); therefore, intrathecal polyclonal B-cell activation might also 
induce nonspecific IgG production in CNS, which inhibits FcγR IIa-mediated interferogenic 
activity.[17, 24] Alternatively, CSF IFN-α might be regulated by other immunologic factors 
than anti-U1RNP Abs in NPSLE. 
Several reports have shown the clinical importance of other IMs in NPSLE patients. 
CSF MCP-1 has been reported as a useful biomarker that differentiates SLE-attributable NP 
manifestations from non-SLE-related manifestations.[9] Our results indicated that the 
elevated CSF MCP-1 level was not specific to CSF anti-U1RNP Ab-positive patients. When 
limited to NPSLE patients with serum anti-U1RNP Abs, however, CSF anti-U1RNP Ab 
positivity appeared to be positively correlated with the elevation of CSF MCP-1 levels. 
Therefore, CSF MCP-1 activation resulting from CNS injuries may stimulate the 
anti-U1RNP Ab production in CNS. We previously suggested the possibility of intrathecal 
anti-U1RNP Ab production by showing U1-70K different autoepitope patterns between 
serum and CSF anti-U1RNP Abs.[7]  
 To date, only our group[7, 25] and a German group[26] have published reports of 
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CSF anti-U1RNP Ab-positive cases. A critical point of our study is the use of RNA-IPP to 
detect anti-U1RNP Abs in CSF. RNA-IPP is the most sensitive and specific immunological 
method for detecting Abs, especially against ‘native’ RBPs.[27] Because less than 20 µL of 
sample is enough for assay, RNA-IPP is more suitable than ELISA for detecting anti-RBP 
Abs in CSF, which usually cannot be obtained in a large amount from patients.  
However, the present study has some limitations. First, because we did not have 
CSF of SLE patients without NP manifestation, it is unclear whether CSF anti-U1RNP Abs 
exist in those patients. Second, other NPSLE-associated auto-Abs such as anti-ribosomal P 
were not investigated. Although we could find Abs against ribosomal antigens such as 
28S-ribosomal protein in the present study, anti-ribosomal P Abs could not be specifically 
detected by RNA-immunoprecipitation assay. Previous studies demonstrated that IL-6 levels 
in CSF may be associated with anti-NR2 Abs.[28] IL-8 and MCP-1 levels appear to be 
associated with other auto-Ab levels more than anti-U1RNP Ab levels. Auto-Abs against 
DNA-binding or associated antigens cannot be detected by RNA-IPP; therefore, an 
association study of anti-non RBP Abs and CSF IMs using other assays is needed.  
In conclusion, CSF anti-U1RNP Abs are associated with the elevated CSF IFN-α 
levels in NPSLE. CSF MCP-1 concentrations correlate with CSF anti-U1RNP Ab levels, 
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Figure 1. Serum and CSF anti-U1RNP and SSA Abs detection by RNA-IPP 
Auto-Abs against RBPs in serum and CSF of NPSLE patients were examined. (1) non-SLE 
control without anti-RBP Abs, (2, 3) NPSLE patients with both serum and CSF anti-U1RNP 
Abs, (4) NPSLE patient with both serum and CSF anti-U1RNP/Sm Abs, (5) secondary 
NPSLE patient with serum anti-U1RNP Abs, (6) NPSLE patients with serum anti-SSA Abs 
and (7) NPSLE patients without anti-RBP Abs.  
T = total RNA, S = serum, C = CSF 
 
Figure 2. Frequency of anti-U1RNP and SSA Abs in serum and CSF of NPSLE patients 
CSF anti-U1RNP Abs are not detected in serum anti-U1RNP Ab-negative patients. CSF 
anti-SSA Abs are infrequently found even in serum anti-SSA Ab-positive NPSLE patients. 
 
Figure 3. Association between serum anti-U1RNP Ab-positivity and CSF IM levels 
CSF levels of IFN-α, IL-8 and MCP-1 were compared among non-NPSLE patients without 
serum anti-U1RNP Abs (control) (n = 15), NPSLE patients without serum anti-U1RNP Abs 
(anti-U1RNP Ab (−), n = 34), and NPSLE patients with serum anti-U1RNP Abs 
(anti-U1RNP Abs (+), n = 48). 
n.s., not significant, **p < 0.01 (compared with control) 
 
Figure 4. Association between CSF anti-U1RNP Ab-positivity and CSF IM levels 
(A) CSF levels of IFN-α, IL-8 and MCP-1 were compared among non-NPSLE patients 
without CSF anti-U1RNP Abs (control) (n = 15), CSF anti-U1RNP Abs-negative NPSLE 
patients (anti-U1RNP Abs (−), including serum anti-U1RNP Ab-negative patients, n = 67), 
and NPSLE with CSF anti-U1RNP Abs (anti-U1RNP Abs (+), n = 15).  
16 
n.s., not significant, *p < 0.05, **p < 0.01 (compared with control) 
(B) CSF levels of IFN-α, IL-8 and MCP-1 were compared between NPSLE patients without 
(CSF −, n = 33) and with CSF anti-U1RNP Abs (CSF +, n = 15). Serum anti-U1RNP 
Ab-negative patients were not included. 
n.s., not significant, *p < 0.05 (compared with CSF anti-U1RNP Ab-negative patients) 
 
Figure 5. Correlation of CSF anti-U1RNP Ab levels and CSF IM concentrations 
Correlation of CSF anti-U1RNP Ab levels with CSF IFN-α or MCP-1 concentrations is 
shown. CSF anti-U1RNP Ab levels were examined by ELISA after a 1:5 dilution.  




Table 1. Anti-U1RNP Abs and NPSLE forms
Total Serum anti-U1RNP CSF anti-U1RNP 
(+) (-) (+) (-)
Patient number 82 48 34 15 67
age at onset (years old) 35.4±14.3 35.1±15.7 38.0±14.3 30.3±13.2 37.6±15.3
female (%) 85 92 76 87 94
Serum anti-U1RNP (+) (%) 59 100 0 100 49
CSF anti-U1RNP (+) (%) 18 31 0 100 0
Aseptic meningitis 4 3 1 1 3
Neurologic Cerebrovascular disease 5 2 3 0 5
syndrome Seizure disorders 6 2 4 0 6
of the CNS Myelopathy 4 3 1 2 2
Transverse myelopathy 1 0 1 0 1
Headache 18 12 6 5 13
(Subtotal) 38 (46%) 22 (46%) 16 (47%) 8 (53%) 30 (45%)
Diffuse Mood disorder 3 2 1 0 3
psychiatric/ Cognitive dysfunction 7 3 4 0 7
neuropsychologica Psychosis 12 7 5 4 8
syndrome Acute confusional state 2 2 0 0 2
(Subtotal) 24 (29%) 14 (29%) 10 (29%) 4 (27%) 20 (30%)
Neuropathy, cranial 9 5 4 1 8
Movement disorder 1 0 1 0 1
Others Polyneuropathy 1 1 0 1 0
Mononeuropathy, single/multiplex 8 5 3 1 7
Acute inflammatory polyradiculoneuropathy 1 1 0 0 1
(Subtotal) 20 (24%) 12 (25%) 8 (24%) 3 (20%) 17 (25%)
RNP, ribonucleoprotein; NPSLE, neuropsychiatric systemic lupus erythematosus; CNS, central nervous system; CSF, cerebrospinal fluid





